Abarelix

Chemical compound

L02BX01 (WHO)

Pharmacokinetic dataProtein binding96–99%Identifiers

IUPAC name

N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparagyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide^[1]

CAS Number

183552-38-7^N

PubChem CID

16131215

IUPHAR/BPS

1188

DrugBank

DB00106^Y

ChemSpider

10482301^Y

UNII

W486SJ5824

KEGG

D02738^Y

ChEBI

CHEBI:337298^Y

ChEMBL

ChEMBL1252^Y

CompTox Dashboard (EPA)

DTXSID20171443

Chemical and physical dataFormulaC₇₂H₉₅ClN₁₄O₁₄Molar mass1416.09 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc3ccc(Cl)cc3)NC(=O)[C@@H](NCc5ccc4ccccc4c5)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O

InChI

InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1^Y
Key:AIWRTTMUVOZGPW-HSPKUQOVSA-N^Y

^NY (what is this?) (verify)

Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist) which is marketed in Germany and the Netherlands. It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.^[2]^[3]

It was originally marketed by Praecis Pharmaceuticals as Plenaxis,^[2] and is now marketed by Speciality European Pharma in Germany^[4] after receiving a marketing authorization in 2005. The drug was introduced in the United States in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severe allergic reactions.^[5] It remains marketed in Germany and the Netherlands however.^[6]

References

^ "Abarelix". PubChem. 2017-07-29.
^ ^a ^b "Abarelix". Drugs.com. Archived from the original on 2018-02-10. Retrieved 2018-01-23.
^ Boccon-Gibod L, van der Meulen E, Persson BE (June 2011). "An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer". Therapeutic Advances in Urology. 3 (3): 127–40. doi:10.1177/1756287211414457. PMC 3159401. PMID 21904569.
^ Pharmazeutische Zeitung online: Abarelix (in German)
^ Minev B (13 January 2011). Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Springer Science & Business Media. pp. 182–. ISBN 978-90-481-9704-0.
^ "Abarelix". Drugs.com. Archived from the original on 2019-08-29. Retrieved 2018-08-27.

GnRHTooltip Gonadotropin-releasing hormone and gonadotropins

GnRH modulators
(incl. analogues)

Agonists	Peptide: Azagly-nafarelin Buserelin Deslorelin Fertirelin Gonadorelin Goserelin Histrelin Lecirelin Leuprorelin (leuprolide) Nafarelin Peforelin Triptorelin
Antagonists	Peptide: Abarelix Cetrorelix Degarelix Ganirelix Non-peptide: Elagolix Linzagolix^† Relugolix (+estradiol/norethisterone acetate)

Gonadotropins

Preparations	Follicle-stimulating hormone Human chorionic gonadotropin Luteinizing hormone Menotropin Urofollitropin

Others
(indirect)

Progonadotropins	Sex steroid antagonists (via disinhibition of the HPG axis): Antiandrogens (e.g., flutamide, bicalutamide, enzalutamide) Antiestrogens/SERMsTooltip Selective estrogen receptor modulators (e.g., tamoxifen, clomifene, enclomifene) Aromatase inhibitors (e.g., anastrozole) GnRH agonists (e.g., GnRHTooltip gonadotropin-releasing hormone)
Antigonadotropins	Sex steroid agonists (via negative feedback on the HPG axis): Androgens/anabolic steroids (e.g., testosterone, nandrolone esters, oxandrolone) D₂ receptor antagonists (prolactin releasers) (incl., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride) Estrogens (incl., bifluranol, estradiol, estradiol esters, ethinylestradiol, diethylstilbestrol, paroxypropione) Progestogens (incl. progestins, e.g., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, medroxyprogesterone acetate, megestrol acetate) Others (mixed or unknown mechanism of action): Danazol Gestrinone Metallibure

Progonadotropins

Sex steroid antagonists (via disinhibition of the HPG axis): Antiandrogens (e.g., flutamide, bicalutamide, enzalutamide)
Antiestrogens/SERMsTooltip Selective estrogen receptor modulators (e.g., tamoxifen, clomifene, enclomifene)
Aromatase inhibitors (e.g., anastrozole)
GnRH agonists (e.g., GnRHTooltip gonadotropin-releasing hormone)

Antigonadotropins

Sex steroid agonists (via negative feedback on the HPG axis): Androgens/anabolic steroids (e.g., testosterone, nandrolone esters, oxandrolone)
D₂ receptor antagonists (prolactin releasers) (incl., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride)
Estrogens (incl., bifluranol, estradiol, estradiol esters, ethinylestradiol, diethylstilbestrol, paroxypropione)
Progestogens (incl. progestins, e.g., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, medroxyprogesterone acetate, megestrol acetate)

Others (mixed or unknown mechanism of action): Danazol
Gestrinone
Metallibure

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

See also: GnRH and gonadotropin receptor modulators; Androgens and antiandrogens; Estrogens and antiestrogens; Progestogens and antiprogestogens

GnRHTooltip Gonadotropin-releasing hormone receptor and gonadotropin receptor modulators

GnRHTooltip Gonadotropin-releasing hormone receptor

Agonists: Peptides: Alarelin
Avorelin
Azagly-nafarelin
Buserelin
Deslorelin
Fertirelin
GnRH
Gonadorelin
Goserelin
Histrelin
Leuprorelin (leuprolide)
Lutrelin
Nafarelin
Peforelin
Salmon GnRH
Triptorelin
Zoptarelin
Zoptarelin doxorubicin

Antagonists: Peptides: Abarelix
Acyline
Azaline B
Cetrorelix
Degarelix
Detirelix
Ganirelix
Iturelix (antide)
LXT-101
Ornirelix (ornitide)
Ozarelix
Prazarelix
Ramorelix
Teverelix (antarelix); Non-peptides: Elagolix
Linzagolix
Opigolix
Relugolix
Sufugolix

Gonadotropin

LH/hCGTooltip Luteinizing hormone/choriogonadotropin receptor	Agonists: Peptides: Choriogonadotropin alfa Human chorionic gonadotropin Luteinizing hormone Lutropin alfa Menotropin (human menopausal gonadotropin)
FSHTooltip Follicle-stimulating hormone receptor	Agonists: Peptides: Corifollitropin alfa Follicle-stimulating hormone Follitropin alfa Follitropin beta Follitropin epsilon Menotropin (human menopausal gonadotropin) Urofollitropin Varfollitropin alfa NAMs: Non-peptides: ADX-61623